Samlyn Capital’s Zymeworks ZYME Stock Holding History

Samlyn Capital’s Portfolio ZYME Stock Details ZYME Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q1	–	Sell	-316,979	Closed	-$14.4M	–	128
2019 Q4	$14.4M	Buy	+316,979	New	+$11.5M	0.3%	70

Other funds holding ZYME

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Fidelity International Hamilton, Bermuda $129B AUM 30.83% 1-Year Est. Return

GPP

Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return

Polar Capital London, United Kingdom $13.5B AUM 55.9% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return

Samlyn Capital's ZYME Position: Q1 2020 in Review

Samlyn Capital sold out of Zymeworks (ZYME) in Q1 2020, closing a stake of 316,979 shares — an estimated $14.4M sold.

Samlyn Capital first reported a position in ZYME in Q4 2019 and held it in 1 quarter. The position peaked at $14.4M in Q4 2019. 116 funds tracked by Wall St. Rank hold ZYME as of Q1 2020.

Samlyn Capital reported no remaining Zymeworks position as of Q1 2020 after selling out during the quarter.
Samlyn Capital sold 316,979 Zymeworks shares in Q1 2020, an estimated $14.4M.
Samlyn Capital first reported a position in Zymeworks in Q4 2019 and held it in 1 quarter.
Samlyn Capital's Zymeworks position peaked at $14.4M in Q4 2019.
116 funds tracked by Wall St. Rank held Zymeworks as of Q1 2020.

Based on Samlyn Capital's 13F filing for Q1 2020, filed 15 May 2020.